Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Zinc finger AN1-type domain 2A (ZFAND2A)
- Target
- ZFAND2A
- Molecular classification
- Zinc finger protein, Heat shock protein (inducible), Stress-response mediator, Other (protein coding gene, not a classic receptor/enzyme/transcription factor)
01
Overview
Zinc finger AN1-type domain 2A (ZFAND2A, AIRAP) is a stress-responsive protein with predicted zinc ion binding activity, primarily localized to the nucleus and endoplasmic reticulum. ZFAND2A expression is tightly regulated by heat shock factor 1 (HSF1) and rapidly induced by heat shock and proteotoxic stressors—including bortezomib—positioning it as a mediator of cellular defense mechanisms against protein misfolding and aggregation. ZFAND2A participates in proteasome-mediated protein catabolism, positive regulation of proteasomal activity, and adapts cell responses to environmental challenges such as arsenic exposure and elevated temperature. It is not considered a classic therapeutic target, but its regulation and activity are relevant in the contexts of cancer therapy and cellular stress adaptation.
- Other names
- AN1-type zinc finger protein 2AAIRAParsenite inducible RNA associated proteinzinc finger, AN1-type domain 2A
02
Mechanism of action
Drug-induced (bortezomib): Proteasome inhibition leads to proteotoxic stress and activation of ZFAND2A via heat shock factor 1 (HSF1)-mediated transcription
03
Biological functions
Zinc ion bindingProteasome-mediated ubiquitin-dependent protein catabolic processProtein targeting to endoplasmic reticulumCellular response to heat shock/proteotoxic stressCellular response to arsenic-containing substancesPositive regulation of proteasomal activity during stress
04
Disease associations
Cancer (expression induced by bortezomib, a cancer therapy)Other (roles in stress adaptation may impact cellular homeostasis in disease but direct disease causality is not established in major databases)
05
Safety considerations
None reported in relation to therapeutic targeting—its induction is part of the normal cellular protective response, not known to cause toxicity
06
Interacting drugs
Bortezomib (induction of ZFAND2A expression observed upon treatment)
07
Biomarkers
Potential marker for cellular stress response, especially heat shock and proteasome inhibition in cancer therapy (e.g., bortezomib sensitivity)
Beyond the preview
Go deeper on Zinc finger AN1-type domain 2A (ZFAND2A).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zinc finger AN1-type domain 2A (ZFAND2A).